Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Alembic Pharma gets...

    Alembic Pharma gets USFDA nod for generic antidepressant drug

    Written by supriya kashyap kashyap Published On 2017-04-09T10:13:42+05:30  |  Updated On 9 April 2017 10:13 AM IST
    Alembic Pharma gets USFDA nod for generic antidepressant drug



    New Delhi : Alembic Pharmaceuticals has received approval from the US health regulator for generic Fluoxetine Hydrochloride tablets used for the treatment of depression and panic disorder.


    The approval is for the generic version of Eli Lilly and Company's Prozac tablets in the same strengths, Alembic Pharma said in a BSE filing.


    The tablets are indicated for treatment of major depressive disorder and obsessive compulsive disorder in adult and paediatric patients, it said.


    They are also indicated for treatment of binge-eating and vomiting behaviour in moderate to severe Bulimia Nervosa and acute treatment of panic disorder, in adult patients.


    "The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Fluoxetine Hydrochloride tablets, 10 mg and 20 mg", it said.


    These tablets have an estimated market size of USD 120 million for 12 months ending December 2015 according to IMS, the company added.


    Alembic Pharma currently has a total of 53 ANDA approvals from the US health regulator.


    The company's stock was trading 0.84 per cent higher at Rs 625 per scrip on BSE.



    AlembicANDAantidepressantantidepressant drugdepressionFluoxetine Hydrochloridemajor depressive disorderspanic disordersUS Food and Drug AdministrationUSFDA
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok